Bayer’s Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use kdunleavy Tue, 05/03/2022 – 15:40 More: Bayer's Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use
read morePfizer sticks to guns on $22B Paxlovid sales despite reports of lagging demand fkansteiner Tue, 05/03/2022 – 11:35 More: Pfizer sticks to guns on B Paxlovid sales despite reports of lagging demand Source: fierce
read moreIncyte says it has added 2nd manufacturing site to remedy Opzelura production problems kdunleavy Tue, 05/03/2022 – 10:56 More: Incyte says it has added 2nd manufacturing site to remedy Opzelura production problems Source: fierce
read moreNo go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program ntaylor Tue, 05/03/2022 – 10:45 More: No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program Source: fierce
read moreBexson expands on-body ketamine delivery work into mental health ntaylor Tue, 05/03/2022 – 10:39 More: Bexson expands on-body ketamine delivery work into mental health Source: fierce
read moreByondis and Medac have entered into a license and collaboration agreement for form of targeted chemotherapy More: Byondis and Medac link up to commercialise trastuzumab duocarmazine Source: News
read more© 1994 - 2022 B.M. Pharmaceuticals